N4 Pharma encouraging data, oncology the quickest route to clinic (Interview)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss encouraging data from its oncology research.

Nigel describes the behavior of Nuvec, explains why now a focus on oncology, work on vaccines, funding and what investors can expect over the coming months.

N4 Pharma is a the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines.

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
N4 Pharma encouraging data, oncology the quickest route to clinic (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions